Skip to main content

Sergio Manresa Vera

Institutions of which they are part

Research technician
Childhood Cancer and Blood Disorders
Vall Hebron Institut de Recerca

Sergio Manresa Vera

Institutions of which they are part

Research technician
Childhood Cancer and Blood Disorders
Vall Hebron Institut de Recerca

Projects

A phase I trial of ABTL0812 in paediatric patients with advanced cancer including neuroblastoma

IP: Lucas Moreno Martín-Retortillo
Collaborators: Cristina Gamez Cenzano, Aroa Soriano Fernández, Luis Riera Soler, Miguel Segura Ginard, Carlota Aguilera Ordoñez, Sergio Manresa Vera
Funding agency: Instituto de Salud Carlos III
Funding: 826760.77
Reference: ICI21/00076
Duration: 01/01/2022 - 31/12/2025

Implementation and new biomarker development for Personalised Medicine for Childhood Cancers in Spain

IP: Lucas Moreno Martín-Retortillo
Collaborators: Aroa Soriano Fernández, Marta Garrido Pontnou, Miguel Segura Ginard, Lorena Valero Arrese, Raquel Hladun Alvaro, Elena Antima Martinez Saez, Marta Sese Faustino, Gabriela Guillén Burrieza, Josep Roma Castanyer, Andrea Vilaplana Blanes, Sergio Manresa Vera, Margarita Ortega Blanco, María Rosario Pérez- Torres Lobato, Asbleidy Carolina Torres Barbosa
Funding agency: Instituto de Salud Carlos III
Funding: 369260
Reference: PMP21/00073
Duration: 01/01/2022 - 31/12/2025

Next generation personalised medicine for childhood cancers

IP: Lucas Moreno Martín-Retortillo
Collaborators: Aroa Soriano Fernández, Jessica Camacho Soriano, Raquel Hladun Alvaro, Gabriela Guillén Burrieza, Andrea Vilaplana Blanes, Lorena Valero Arrese, Sergio Manresa Vera, Mariona Morell Daniel
Funding agency: Instituto de Salud Carlos III
Funding: 214170
Reference: PI21/01661
Duration: 01/01/2022 - 30/06/2026

Related news

During the meeting, the role of the Vall d'Hebron Paediatric Research Hub in promoting research on children and adolescents was highlighted.

The meeting was an opportunity to get to know projects from both institutions and to promote interaction between professionals.

A study jointly led by the Hospital Clínic of Barcelona and the Vall d'Hebron Research Institute (VHIR) confirms the effectiveness of neonatal screening in reducing morbidity among children with sickle cell disease (SCD).

Related professionals

Mª Teresa Fernández Taranilla

Mª Teresa Fernández Taranilla

Administration and Management
Cardiovascular Diseases
Read more
Albert Selva O'Callaghan

Albert Selva O'Callaghan

Main researcher
Systemic Diseases
Read more
Anna Vilarrodona Serrat

Anna Vilarrodona Serrat

Main researcher
Donation and transplantation of organs, tissues and cells
Read more
M Jesus Arevalo  Navines

M Jesus Arevalo Navines

Postdoctoral researcher
Clinical Neuroimmunology
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.